P186 Single centre experience of tocilizumab in COVID 19 pneumonia

Abstract

P186 Table 1Clinical parameters of the COVID 19 pneumonia patients who received tocilizumab between January and February 2021Dexamethasone (Control group) Dexamethasone+ Tocilizumab p value Total 38 47 Age Median [IQR] 61.5 54 SF ratio Median [IQR] 106.67 106.67 Gender Male 21 36 Female 17 11 Ethnicity British/White 25 30 Any other white background 1 8 Asian 5 11 Others 8 6 Outcome Death 17 8 0.008 Need for NIV/HFNO 9 27 0.002 ITU admission 12 22 0.18 Need for intubation 4 13 0.06 Length of Hospital Stay Median [IQR] 6 12 <0.001 ConclusionThis study showed that tocilizumab may be associated with mortality benefit but no reduction in the rate of progression to intubation or need of NIV/HFNO. Further data with larger patient cohort is required to ascertain the benefits of tocilizumab in COVID 19 pneumonia.